Free Trial
→ Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown” (From Paradigm Press) (Ad)tc pixel Free THMO Stock Alerts

ThermoGenesis (THMO) Competitors

ThermoGenesis logo
Compare

THMO vs. HTGMQ, BTTX, AFIB, ADTX, and CMRA

Should you buy ThermoGenesis stock or one of its competitors? ThermoGenesis's main competitors and comparable companies include HTG Molecular Diagnostics (HTGMQ), Better Therapeutics (BTTX), Acutus Medical (AFIB), Aditxt (ADTX), and Comera Life Sciences (CMRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does ThermoGenesis compare to HTG Molecular Diagnostics?

ThermoGenesis (NASDAQ:THMO) and HTG Molecular Diagnostics (NASDAQ:HTGMQ) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

ThermoGenesis has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market. Comparatively, HTG Molecular Diagnostics has a beta of 3, suggesting that its stock price is 200% more volatile than the broader market.

5.8% of ThermoGenesis shares are held by institutional investors. 78.0% of ThermoGenesis shares are held by company insiders. Comparatively, 2.6% of HTG Molecular Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

ThermoGenesis has higher revenue and earnings than HTG Molecular Diagnostics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ThermoGenesis$9.61M0.00-$17.98M-$5.14N/A
HTG Molecular Diagnostics$6.37M0.00-$21.59MN/AN/A

Company Net Margins Return on Equity Return on Assets
ThermoGenesisN/A N/A N/A
HTG Molecular Diagnostics N/A N/A N/A

In the previous week, ThermoGenesis' average media sentiment score of 0.00 equaled HTG Molecular Diagnostics'average media sentiment score.

Company Overall Sentiment
ThermoGenesis Neutral
HTG Molecular Diagnostics Neutral

Summary

ThermoGenesis beats HTG Molecular Diagnostics on 5 of the 6 factors compared between the two stocks.

How does ThermoGenesis compare to Better Therapeutics?

ThermoGenesis (NASDAQ:THMO) and Better Therapeutics (NASDAQ:BTTX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

ThermoGenesis has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, Better Therapeutics has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
ThermoGenesisN/A N/A N/A
Better Therapeutics N/A N/A N/A

In the previous week, ThermoGenesis' average media sentiment score of 0.00 equaled Better Therapeutics'average media sentiment score.

Company Overall Sentiment
ThermoGenesis Neutral
Better Therapeutics Neutral

5.8% of ThermoGenesis shares are held by institutional investors. Comparatively, 34.0% of Better Therapeutics shares are held by institutional investors. 78.0% of ThermoGenesis shares are held by insiders. Comparatively, 51.4% of Better Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

ThermoGenesis has higher revenue and earnings than Better Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ThermoGenesis$9.61M0.00-$17.98M-$5.14N/A
Better TherapeuticsN/AN/A-$39.76M-$0.39N/A

Summary

ThermoGenesis beats Better Therapeutics on 5 of the 7 factors compared between the two stocks.

How does ThermoGenesis compare to Acutus Medical?

ThermoGenesis (NASDAQ:THMO) and Acutus Medical (NASDAQ:AFIB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

ThermoGenesis has higher revenue and earnings than Acutus Medical.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ThermoGenesis$9.61M0.00-$17.98M-$5.14N/A
Acutus Medical$7.16M0.00-$81.66M-$0.11N/A

In the previous week, ThermoGenesis' average media sentiment score of 0.00 equaled Acutus Medical'saverage media sentiment score.

Company Overall Sentiment
ThermoGenesis Neutral
Acutus Medical Neutral

ThermoGenesis has a net margin of 0.00% compared to Acutus Medical's net margin of -272.74%. ThermoGenesis' return on equity of 0.00% beat Acutus Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
ThermoGenesisN/A N/A N/A
Acutus Medical -272.74%-311.64%-11.57%

ThermoGenesis has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market. Comparatively, Acutus Medical has a beta of 5.73, suggesting that its stock price is 473% more volatile than the broader market.

5.8% of ThermoGenesis shares are owned by institutional investors. Comparatively, 56.9% of Acutus Medical shares are owned by institutional investors. 78.0% of ThermoGenesis shares are owned by company insiders. Comparatively, 5.2% of Acutus Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

ThermoGenesis beats Acutus Medical on 7 of the 10 factors compared between the two stocks.

How does ThermoGenesis compare to Aditxt?

Aditxt (NASDAQ:ADTX) and ThermoGenesis (NASDAQ:THMO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

In the previous week, Aditxt had 1 more articles in the media than ThermoGenesis. MarketBeat recorded 1 mentions for Aditxt and 0 mentions for ThermoGenesis. Aditxt's average media sentiment score of 0.00 equaled ThermoGenesis'average media sentiment score.

Company Overall Sentiment
Aditxt Neutral
ThermoGenesis Neutral

ThermoGenesis has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. ThermoGenesis' return on equity of 0.00% beat Aditxt's return on equity.

Company Net Margins Return on Equity Return on Assets
Aditxt-360,152.50% -374.60% -105.93%
ThermoGenesis N/A N/A N/A

ThermoGenesis has higher revenue and earnings than Aditxt. Aditxt is trading at a lower price-to-earnings ratio than ThermoGenesis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aditxt$14.34K0.18-$41.71M-$100.79 thousandN/A
ThermoGenesis$9.61M0.00-$17.98M-$5.14N/A

Aditxt has a beta of 1.34, indicating that its share price is 34% more volatile than the broader market. Comparatively, ThermoGenesis has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market.

Given ThermoGenesis' higher possible upside, analysts clearly believe ThermoGenesis is more favorable than Aditxt.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aditxt
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
ThermoGenesis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

15.5% of Aditxt shares are owned by institutional investors. Comparatively, 5.8% of ThermoGenesis shares are owned by institutional investors. 0.0% of Aditxt shares are owned by company insiders. Comparatively, 78.0% of ThermoGenesis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

ThermoGenesis beats Aditxt on 8 of the 13 factors compared between the two stocks.

How does ThermoGenesis compare to Comera Life Sciences?

ThermoGenesis (NASDAQ:THMO) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

ThermoGenesis has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

5.8% of ThermoGenesis shares are held by institutional investors. 78.0% of ThermoGenesis shares are held by insiders. Comparatively, 8.9% of Comera Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, ThermoGenesis' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
ThermoGenesis Neutral
Comera Life Sciences Neutral

Company Net Margins Return on Equity Return on Assets
ThermoGenesisN/A N/A N/A
Comera Life Sciences N/A N/A N/A

ThermoGenesis has higher revenue and earnings than Comera Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ThermoGenesis$9.61M0.00-$17.98M-$5.14N/A
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A

Summary

ThermoGenesis beats Comera Life Sciences on 6 of the 7 factors compared between the two stocks.

Get ThermoGenesis News Delivered to You Automatically

Sign up to receive the latest news and ratings for THMO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding THMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

THMO vs. The Competition

Export
MetricThermoGenesisLaboratory apparatus & furniture IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1K$1K$7.14B$13.26B
Dividend YieldN/AN/A2.53%17.36%
P/E Ratio0.00N/A274.3226.20
Price / SalesN/A0.00609.2488.33
Price / CashN/AN/A27.2234.70
Price / BookN/AN/A11.236.40
Net Income-$17.98M-$17.98M$3.49B$381.07M

ThermoGenesis Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
THMO
ThermoGenesis
N/AN/AN/AN/A$1K$9.61MN/A25
HTGMQ
HTG Molecular Diagnostics
N/AN/AN/AN/A$0.00$6.37MN/A53
BTTX
Better Therapeutics
N/AN/AN/AN/A$4KN/AN/A40
AFIB
Acutus Medical
N/AN/AN/AN/A$3K$7.16MN/A85
ADTX
Aditxt
0.0269 of 5 stars		$0.00
-5.9%		N/A-100.0%$3K$14.34KN/A60

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:THMO) was last updated on 10/6/2026 by MarketBeat.com Staff.
From Our Partners
This smart glasses tech is bringing the screen to your eyes
Global AI smart-glasses shipments surged 263% in the first half of 2026, and Citi projects the market could re...
The Tomorrow Investor | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
Musk says UBI is coming. I say it's already here.
Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...
Freedom Financial | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
I've seen this movie before (last time: 17,556%)
My track record speaks for itself... KDA: 17,556%. PRE: 3,900%. OCEAN: 2,650%. Every single one was called ...
Crypto 101 Media | Sponsoredtc pixel
The case for $20,000 gold before year end
President Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and A...
Stansberry Research | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel